Answers are grounded in this paper and cite their sources.
BACKGROUND This study investigated the prognostic factors of bone metastases from lung cancer. MATERIAL AND METHODS From March 2014 to March 2015, 168 patients with bone metastases from lung cancer treated at our hospital were included and the clinical data were reviewed. The Kaplan-Meier survival curves were calculated and analyzed using the log-rank univariate test. Multivariate regression analysis was conducted using Cox's regression model. RESULTS The overall median survival of the 168 patients was 13 months. The 1-year survival was 54.3% and the 2-year survival was 12.9%. Univariate regression analysis indicated that the pathologic types, number of bone metastases, clinical stage, ECOG scores, and serum ALP levels were significantly correlated with survival (P<0.05). Multivariate regression analysis indicated that the number of bone metastases, clinical stage, and serum ALP levels were significantly correlated with prognosis (P<0.05). The risk associated with multiple bone metastases was 1.72 times of that of single bone metastasis (P=0.029); the risk associated with advanced clinical stage was 1.49 times of that of early clinical stage (P=0.001); and the risk associated with a high serum ALP level was 1.75 times of that of the low serum ALP level (P=0.006). CONCLUSIONS Pathologic types, number of bone metastases, clinical stage, ECOG scores, and serum ALP levels were the prognostic factors for bone metastases from lung cancer.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: